#1 Clinical Trials Search in Europe

Ads-015

This article discusses the clinical trials of ARO-RAGE (ADS-015), an investigational inhalation solution being studied for the treatment of inflammatory lung disease, particularly asthma. The trials aim to assess the safety, tolerability, and effectiveness of ARO-RAGE in both healthy volunteers and patients with mild to moderate asthma. The study will evaluate different dosages and their effects on lung function and inflammation markers.

Table of Contents

What is ARO-RAGE (ADS-015)?

ARO-RAGE, also known as ADS-015, is a new investigational medication being developed for the treatment of inflammatory lung diseases[1]. It is a synthetic, double-stranded siRNA (small interfering RNA) molecule that has been specially designed to target inflammation in the lungs[1].

How does it work?

ARO-RAGE works by targeting a specific protein called RAGE (Receptor for Advanced Glycation End-products). RAGE is involved in inflammatory processes in the lungs. By reducing the activity of RAGE, ARO-RAGE aims to decrease inflammation and potentially improve lung function in patients with inflammatory lung diseases[1].

What conditions does it treat?

ARO-RAGE is being investigated for the treatment of inflammatory lung diseases, with a specific focus on asthma. The current clinical trial is studying its effects in patients with mild to moderate asthma and those with high levels of airway inflammation[1].

How is it administered?

ARO-RAGE is administered as an inhalation solution using a special device called the Pari eFlow Type 30XL nonvented vibrating mesh nebulizer system. This device turns the medication into a fine mist that can be inhaled directly into the lungs[1].

Current research

ARO-RAGE is currently being studied in a Phase 1/2a clinical trial. This study aims to evaluate the safety, tolerability, and effectiveness of ARO-RAGE in healthy volunteers and patients with inflammatory lung disease, particularly asthma[1]. The trial includes several groups (cohorts) of participants who will receive different doses of the medication or a placebo.

Who can participate in the study?

The study is looking for participants who meet specific criteria, including:

  • Adults aged 18-65 years
  • Diagnosed with asthma for at least 12 months
  • Currently using asthma controller medications
  • Non-smokers or former smokers who quit at least 6 months ago

There are also several exclusion criteria, such as recent respiratory infections, use of certain medications, or other medical conditions that might interfere with the study results[1].

Potential benefits

While the effectiveness of ARO-RAGE is still being studied, potential benefits for patients with inflammatory lung diseases could include:

  • Reduced lung inflammation
  • Improved lung function
  • Better control of asthma symptoms

However, it’s important to note that these potential benefits are still being investigated and have not been proven yet[1].

Safety considerations

As with any investigational medication, there may be risks and side effects associated with ARO-RAGE. The current study is designed to carefully monitor participants for any adverse effects. Some safety measures in the study include:

  • Regular check-ups and lung function tests
  • Monitoring of vital signs and laboratory tests
  • Careful selection of participants to minimize risks

Participants in the study will be closely monitored by healthcare professionals throughout the trial period[1].

Aspect Details
Drug Name ARO-RAGE (ADS-015)
Drug Type Synthetic, double-stranded siRNA duplex conjugated to an αvβ6 integrin-targeting ligand
Administration Inhalation solution using Pari eFlow Type 30XL nonvented vibrating mesh nebulizer system
Target Condition Inflammatory Lung Disease, particularly asthma
Study Phase Phase 1/2a
Primary Objective Assess safety and tolerability in healthy volunteers and patients
Secondary Objectives Evaluate lung function (FEV1, FVC, DLCO), pharmacokinetics, and pharmacodynamics
Study Population Healthy volunteers and patients with mild to moderate asthma
Dosing Schedule Two doses: Day 1 and Day 29
Key Inclusion Criteria Physician-diagnosed asthma, stable medication regimen, specific lung function parameters
Key Exclusion Criteria Recent respiratory infections, use of certain medications, significant comorbidities

FAQ

  • What is ARO-RAGE (ADS-015)? ARO-RAGE (ADS-015) is an investigational inhalation solution being studied for the treatment of inflammatory lung disease, particularly asthma. It is a synthetic, double-stranded siRNA duplex conjugated to an αvβ6 integrin-targeting ligand.
  • What is the main objective of the clinical trials for ARO-RAGE? The main objective is to assess the safety and tolerability of ARO-RAGE in normal healthy volunteers (NHVs) and patients with inflammatory lung disease, particularly asthma.
  • How is ARO-RAGE administered in the trials? ARO-RAGE is administered as an inhalation solution using a Pari eFlow Type 30XL nonvented vibrating mesh nebulizer system.
  • What types of patients are included in the ARO-RAGE trials? The trials include both healthy volunteers and patients with mild to moderate asthma. Some cohorts specifically target patients with high levels of airway inflammation, as indicated by high FeNO (fractional exhaled nitric oxide) levels.
  • How long does the study last for each participant? While the exact duration isn't specified, participants receive two doses of the study drug, once on Day 1 and once on Day 29. The study includes multiple follow-up visits to assess safety and efficacy.

Ongoing Clinical Trials on Ads-015

  • Study on the Effects of ARO-RAGE (ADS-015) for Patients with Inflammatory Lung Disease

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Poland Spain

Glossary

  • ARO-RAGE (ADS-015): An investigational inhalation solution being studied for the treatment of inflammatory lung disease, particularly asthma. It is a synthetic, double-stranded siRNA duplex conjugated to an αvβ6 integrin-targeting ligand.
  • siRNA: Small interfering RNA, a type of RNA molecule that can interfere with the expression of specific genes.
  • Inflammatory Lung Disease: A group of disorders characterized by inflammation in the lungs, which can cause breathing difficulties and other respiratory symptoms.
  • Asthma: A chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to breathing difficulties, wheezing, and coughing.
  • FeNO: Fractional exhaled nitric oxide, a biomarker of airway inflammation used to assess and monitor asthma.
  • FEV1: Forced Expiratory Volume in 1 second, a measure of lung function that represents the amount of air a person can forcefully exhale in one second.
  • FVC: Forced Vital Capacity, the total amount of air exhaled during a forced breath.
  • DLCO: Diffusing Capacity for Carbon Monoxide, a test that measures how well oxygen passes from the lungs into the blood.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-aro-rage-ads-015-for-patients-with-inflammatory-lung-disease/